PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids

Phase 1

Completed

Conditions: Healthy Female Volunteers

Interventions: Drug: PF-06700841
Drug: Ethinyl estradiol (EE) and levonorgestrel (LN)

First Posted Date: 2020-02-12

Last Posted Date: 2020-11-13

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT04267250

Locations: 🇺🇸
Quotient Sciences Screening Office, Coral Gables, Florida, United States
🇺🇸
Quotient Sciences-Miami, Miami, Florida, United States

A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day

Completed

Conditions: Arthritis Rheumatoid

First Posted Date: 2020-02-12

Last Posted Date: 2023-05-22

Lead Sponsor: Pfizer

Target Recruit Count: 298

Registration Number: NCT04267380

Locations: 🇺🇸
Pfizer, New York, New York, United States

Renal Impairment Study of PF-06700841

Phase 1

Completed

Conditions: Healthy Volunteer
Renal Impairment

Interventions: Drug: PF-06700841

First Posted Date: 2020-02-07

Last Posted Date: 2024-01-22

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT04260464

Locations: 🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸
Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Research Pharmacy, Miami, Florida, United States
🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS

Phase 2

Completed

Conditions: Group B Streptococcal Infections

Interventions: Biological: Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)

First Posted Date: 2020-02-06

Last Posted Date: 2021-10-13

Lead Sponsor: Pfizer

Target Recruit Count: 151

Registration Number: NCT04258995

Locations: 🇺🇸
J. Lewis Research, Inc./ Foothill Family Clinic South, Salt Lake City, Utah, United States
🇺🇸
Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸
Kentucky Pediatric & Adult Research Inc., Bardstown, Kentucky, United States

and more 1 locations

A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: tafamidis
Drug: rosuvastatin

First Posted Date: 2020-02-05

Last Posted Date: 2020-09-10

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04253353

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy

Terminated

Conditions: Duchenne Muscular Dystrophy (DMD)

Interventions: Device: Activity Monitor

First Posted Date: 2020-02-05

Last Posted Date: 2021-10-15

Lead Sponsor: Pfizer

Target Recruit Count: 2

Registration Number: NCT04254172

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

Phase 1

Completed

Conditions: Healthy
Sickle Cell Anemia

Interventions: Biological: PF-07209326
Biological: Placebo

First Posted Date: 2020-02-05

Last Posted Date: 2023-12-18

Lead Sponsor: Pfizer

Target Recruit Count: 52

Registration Number: NCT04255875

Locations: 🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸
Howard University College of Medicine, Washington, District of Columbia, United States
🇺🇸
Lee Health - Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States

and more 11 locations

Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD

Phase 2

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Voxelotor

First Posted Date: 2020-01-30

Last Posted Date: 2023-11-21

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT04247594

Locations: 🇬🇧
Homerton University, London, United Kingdom
🇬🇧
Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
🇬🇧
King's College Hospital, London, United Kingdom

and more 3 locations

Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to <17 Years Undergoing MRI Scans

Phase 4

Completed

Conditions: MRI Sedation

Interventions: Drug: dexmedetomidine
Drug: propofol

First Posted Date: 2020-01-23

Last Posted Date: 2022-11-16

Lead Sponsor: Pfizer

Target Recruit Count: 128

Registration Number: NCT04237792

Locations: 🇯🇵
National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan
🇺🇸
Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States
🇺🇸
University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States

and more 20 locations

Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2020-01-21

Last Posted Date: 2022-01-11

Lead Sponsor: Pfizer

Target Recruit Count: 207

Registration Number: NCT04234698

Locations: 🇨🇴
Pfizer Investigational Site, Bogota, Cundinamarca, Colombia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy